09966.HK
Alphamab Oncology
HKSE · Healthcare · Biotechnology · CN
HKD 6.49
−0.92%Year over year
Reported trailing growth
- Revenue
- -34.6%
- EBITDA
- —
- EBIT
- —
- EPS
- —
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- -43.3%
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +49.0%
- EBITDA
- —
- EBIT
- —
- Net income
- —
- EPS
- —
- Free cash flow
- —
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026